Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: A potential mechanism to lower plasma triglycerides

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1358-1364

  Dallinga Thie, Geesje M ^a,b   Berk Planken, Ingrid I L ^b   Bootsma, Aart H ^b   Jansen, Hans ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CELL SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PYRROLES; TRIGLYCERIDES;

EID: 2542499183     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1358     Document Type: Article

References (46)

1. Hokanson JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta-analysis of population based prospective studies. J Cardiovasc Res 3:213-219, 1996
2. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97:1029-1036, 1998
3. Kissebah AH, Alfarsi S, Adams PW: Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism 30:856-868, 1981
4. Howard BV, Reitman JS, Vasquez B, Zech L: Very-low-density lipoprotein triglyceride metabolism in non-insulin-dependent diabetes mellitus: relationship to plasma insulin and free fatty acids. Diabetes 32: 271-276, 1983
5. Wilson DE, Kwong LK, Elbein SC, Lalouel JM: Genetic predisposition to hyperlipidaemia in diabetes: the end of the beginning. J Intern Med Suppl 736:53-61, 1994
6. Wang C, McConathy WJ, Kloer HJ, Alaupox4c P: Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoproein C-III. J Clin Invest 75:384-390, 1985
7. Brown WV, Baginsky ML: Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 46:375-382, 1972
8. Windler E, Chao Y, Havel RJ: Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat: opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 255: 8303-8307, 1980
9. Chao YS, Jones AL, Hradek GT, Windler EE, Havel RJ: Autoradiographic localization of the sites of uptake, cellular transport, and catabolism of low density lipoproteins in the liver of normal and estrogen-treated rats. Proc Natl Acad Sci U S A 78:597-601, 1981
10. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL: Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science 249:790-793, 1990
11. Aalto-Setala K, Fisher EA, Chen X, Chajek-Saul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL: Mechanism of hypertriglyceridemia in human apolipoprotein C-III transgenic mice. J Clin Invest 90:1889-1900, 1992
12. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL: Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 37:1802-1811, 1996
13. Jong MC, Rensen PC, Dahlmans VE, van der BH, Van Berkel TJ, Havekes LM: Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 42:1578-1585, 2001
14. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 269:23610-23616, 1994
15. Schonfeld G, George PK, Miller J, Reilly P, Witztum JL: Apolipoprotein C-II and C-III levels in hypertriglyceridemia. Metabolism 28:1001-1010, 1979
16. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, NorthJD, Gilligan M, Gambert P, Ball MJ: Variation at the apo AI/ CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 87:239-247, 1991
17. Alaupovic P, Bard JM, Tavella M, Shafer D: Identification of apoB-containing lipoprotein families in NIDDM. Diabetes 41 (Suppl. 2):18-25, 1992
18. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alupovic P: Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 25:258-262, 1999
19. Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL: The effect of aggressive and moderate lowering of LDL cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis 146:369-379, 1999
20. Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS: Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 41:706-718, 2000
21. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI Evidence that apoliporptein CIII inhibits catabolism of triglyceride-rich lipoprotein lipase in vivo. J Clin Invest 78:1287-1295, 1986
22. Boyle KE, Phillips MC, Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta Protein Struct Mol Enzymol 1430:302-312, 1999
23. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P: Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia 43:703-708, 2000
24. Tiret L, Gerdes C, Murphy MJ, Dallongeville J, Nicaud V, O'Reilly DS, Beisiegel U, De Backer G: Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary heart disease: the EARS II study. Eur J Clin Invest 30:578-585, 2000
25. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90:42-49, 1994
26. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102: 1886-1892, 2000
27. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 81: 470-476, 1990
28. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49:167-177, 2000
29. Dallongeville J, Fruchart JC, Maigret P, Bertolini S, Bon GB, Campbell MM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C: Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 3:103-110, 1998
30. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24:1335-1341, 2001
31. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811, 2003
32. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ: Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164:129-145, 2002
33. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23 (Suppl. 1):S4-S19, 2000
34. Friedewald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 18:499-502, 1972
35. Jansen H, Hop W, Tol Av, Bruschke AVG, Birkenhäger JC: Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 107:45-54, 1994
36. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P: Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The EC-TIM study. J Lipid Res 37:508-517, 1996
37. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 17:715-722, 1997
38. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetière P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetalogia 32:300-304, 1989
39. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI: Intermediate density lipoproteins and progression of CAD. Lancet 2:62-65, 1987
40. Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R: IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 48:127-138, 2000
41. Tornoci L, Scheraldi CA, Li X, Ide H, Goldberg IJ, Le NA: Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. J Lipid Res 34:1793-1803, 1993
42. Barr SI, Kottke BA, Mao SJ: Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Am J Clin Nutr 34: 191-198, 1981
43. Huff MW, Breckenridge WC, Strong WL, Wolfe BM: Metabolism of apolipoproteins C-II, C-III, and B in hypertriglyceridemic men: changes after heparin-induced lipolysis. Arterioscler Thromb 8:471-479, 1988
44. Tomiyasu K, Walsh BW, Ikewaki K, Judge H, Sacks FM: Differential metabolism of human VLDL according to content of apoE and apoC-III. Arterioscler Thromb Vasc Biol 21:1494-1500, 2001
45. Bukberg PR, Le NA, Ginsberg HN, Gibson JC, Goldman LC, Brown WV: Direct measurement of apoprotein C-III specific activity in 125I-labeled very low density lipoproteins using immunoaffinity chromatography. J Lipid Res 24:1251-1260, 1983
46. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fiévet C, Auwerx J: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 452:160-164, 1999